Given its role in cancer progression, CHRNA3 is being investigated as a potential therapeutic target. Inhibitors that can block the activity of the receptors involving the CHRNA3 subunit might be effective in slowing down or preventing the progression of cancer. Targeted therapies that modulate the activity of CHRNA3 could provide a novel approach in the treatment of cancers where this gene plays a significant role.
